Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Double-blind Randomized Placebo-Controlled Studies of Filgotinib in Moderately to Severely Active Crohn's Disease
2016-001367-36Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of filgotinib in Crohn's disease (4 cohorts), sponsored by Gilead Sciences. Primary endpoints: Primary endpoint – Cohort A Induction and Maintenance endpoints. Started Dec 2016; status: completed.
02
Drugs
filgotinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2016-001367-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001367-36.